Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Two Dozen-Plus Biotechs Went Public This Year—With More In The Works

In this week’s edition of InnovationRx, the bumper crop of biotech IPOs, Isomorphic’s reported $40 billion valuation fundraise, and the impact of drugmakers’ gifts to doctors.

Two Dozen-Plus Biotechs Went Public This Year—With More In The Works

We haven't written up this one. Forbes has the full story — the link below goes straight to it.

Read the original at forbes.com →

More in Finance & Markets

More from Wednesday 14 October →